Levofloxacin hydrochloride  (Synonyms: (-)-Ofloxacin hydrochloride)

Levofloxacin hydrochloride is an orally active antibiotic. Levofloxacin inhibits DNA gyrase and topoisomerase IV activity, inducing Apoptosis. Levofloxacin hydrochloride has antibacterial activity against both Gram-positive and Gram-negative bacteria. Levofloxacin hydrochloride exhibits anticancer activity against lung cancer. Levofloxacin hydrochloride has anti-acnegenic, anxiogenic, and analgesic effects. Levofloxacin hydrochloride shortens sleep duration in mice. Levofloxacin hydrochloride can be used in the research of infectious diseases (such as tuberculosis, chronic periodontitis, bacterial infections associated with stable COPD, and BK viremia) and lung cancer^{[1][2][3][4][5][6][7][8][9][10]}.

Levofloxacin hydrochloride inhibits the growth of 18 drug-susceptible Mycobacterium tuberculosis strains with MICs ranging from 0.25 to 1.0 μg/mL and a MIC₅₀ of 0.5 μg/mL^[4].
Levofloxacin (24 h) hydrochloride exhibits strong bactericidal activity against biofilm-forming sessile cells of Pseudomonas aeruginosa^[8].
Levofloxacin (50-200 μg/mL; 24-72 h) hydrochloride inhibits proliferation and induces apoptosis of lung cancer cells (A549, H3255, NCL-69, H460) through inducing mitochondrial dysfunction and oxidative damage^[9].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Levofloxacin (10.7 mg/kg; i.p., once daily for 10 days or 3 weeks) hydrochloride time-dependently induces toxic effects on liver and heart in albino mice^[3].
Levofloxacin (50-300 mg/kg; p.o. via esophageal cannula; six times weekly; 4 weeks) hydrochloride exerts dose-dependent anti-Mycobacterium tuberculosis activity in female outbred Swiss mice^[4].
Levofloxacin (10-40 mg/kg, i.p.) hydrochloride exerts anxiogenic-like effect in rats and shortens Pentobarbital-induced sleeping time, exhibits analgesic activity in mice^[10].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

397.83

C₁₈H₂₁ClFN₃O₄

177325-13-2

Solid

White to off-white

[H]Cl.O=C(C(C1=O)=CN2[C@@H](C)COC3=C(N4CCN(C)CC4)C(F)=CC1=C23)O

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

• [1]. Drlica K, et al. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92.  [Content Brief]

  [2]. Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52.  [Content Brief]

  [3]. Rand A, et al. Effect of levofloxacin on some body tissues in mice. Effect of levofloxacin on some body tissues in mice. Iraqi Journal of Veterinary Sciences, 2021.

  [4]. JI B, et al. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 Jun;39(6):1341-4.  [Content Brief]

  [5]. Siva R, et al. Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis. 2014 Feb 7;9:179-86.  [Content Brief]

  [6]. Pradeep AR, et al. Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Investig Clin Dent. 2015 Aug;6(3):170-8.  [Content Brief]

  [7]. Lee BT, et al. Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial. Clin J Am Soc Nephrol. 2014 Mar;9(3):583-9.  [Content Brief]

  [8]. Ishida H, et al. In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1998 Jul;42(7):1641-5.  [Content Brief]

  [9]. Song M, et al. Antibiotic drug levofloxacin inhibits proliferation and induces apoptosis of lung cancer cells through inducing mitochondrial dysfunction and oxidative damage. Biomed Pharmacother. 2016 Dec;84:1137-1143.  [Content Brief]

  [10]. Erden BF, et al. Antidepressant, anxiogenic, and antinociceptive properties of levofloxacin in rats and mice. Pharmacol Biochem Behav. 2001 Mar;68(3):435-41.  [Content Brief]